Loading
New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer.
Manish Shah leads gastrointestinal oncology at Weill Cornell Medicine in New York. He was first author of the 2023 Nature Medicine report of GLOW, in which zolbetuximab plus CAPOX lengthened progression-free and overall survival in claudin 18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma. His research covers the molecular classification of gastric cancer and its differences between Asian and Western patients.
| Title | Journal | Year |
|---|---|---|
| GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | Nature Medicine | 2023 |
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine and the tag trialist.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer.